Chai is building foundation models for drug discovery, specifically to predict interactions between molecules so they could be reprogramed for cures. Read More
OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation
Chai is building foundation models for drug discovery, specifically to predict interactions between molecules so they could be reprogramed for cures.
Related Posts
OpenAI COO says ‘we have not yet really seen AI penetrate enterprise business processes’
Earlier this month, OpenAI launched a new platform called OpenAI Frontier for enterprises to build…
Max Hodak is more worried about Twitter than brain-computer interface hacking
This week on StrictlyVC Download, Connie Loizos speaks with Science Corp founder Max Hodak to…
Google’s Trends Explore page gets new Gemini capabilities
The Trends Explore page for users to analyze search interest just got a major upgrade.…